Generate Biomedicines (NASDAQ:GENB) Shares Gap Up – Still a Buy?

Generate Biomedicines Inc (NASDAQ:GENB)’s share price gapped up prior to trading on Wednesday. The stock had previously closed at $13.21, but opened at $13.87. Generate Biomedicines shares last traded at $14.9610, with a volume of 310,057 shares changing hands.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on GENB shares. Wall Street Zen downgraded Generate Biomedicines from a “hold” rating to a “sell” rating in a research report on Saturday, October 17th. Weiss Ratings raised Generate Biomedicines from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 25th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Generate Biomedicines in a report on Monday, October 5th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Generate Biomedicines currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.40.

Generate Biomedicines Price Performance

The business’s 50 day moving average is $15.03 and its 200-day moving average is $14.16.

Generate Biomedicines (NASDAQ:GENB) last posted its earnings results on Thursday, August 6th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The firm had revenue of $6.31 million for the quarter. On average, equities analysts anticipate that Generate Biomedicines Inc will post -2.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Summa Corp. acquired a new position in Generate Biomedicines in the third quarter valued at approximately $250,000. Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Generate Biomedicines by 103.1% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 78,531 shares of the company’s stock worth $1,180,000 after buying an additional 39,866 shares in the last quarter. Magnus Financial Group LLC grew its position in shares of Generate Biomedicines by 39.4% during the 3rd quarter. Magnus Financial Group LLC now owns 21,750 shares of the company’s stock worth $327,000 after buying an additional 6,150 shares during the period. Bank Pictet & Cie Europe AG acquired a new stake in shares of Generate Biomedicines during the 3rd quarter worth approximately $1,168,000. Finally, Banque Pictet & Cie SA acquired a new stake in shares of Generate Biomedicines during the 3rd quarter worth approximately $26,631,000.

About Generate Biomedicines

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence, machine learning and protein engineering to design novel protein-based medicines. Its platform is intended to identify and develop therapeutic proteins with desired biological properties, potentially shortening the time required to discover new drug candidates.

The company’s research activities focus on applying computational biology and laboratory experimentation to create medicines for a range of diseases, including conditions in immunology, inflammation, oncology and other areas of significant unmet medical need.